Immediate hypersensitivity reactions to parenteral cyclosporine in patients with thalassemia major undergoing hematopoietic stem cell transplantation: a case report and review of the literature
Open Access
- 11 November 2024
- journal article
- research article
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-7
Abstract
Allogeneic hematopoietic stem cell transplantation is a definitive cure for eligible patients with thalassemia major, and calcineurin inhibitors are essential for preventing graft-versus-host disease. Although invaluable, there are few reports of life-threatening hypersensitivity reactions associated with calcineurin inhibitors. These reactions are generally rare but seem to be more prevalent among patients with thalassemia. Herein, we retrospectively report four cases of patients with thalassemia major who developed hypersensitivity reactions to parenteral cyclosporine. The cases include one 19-year-old Caucasian female and three Caucasian males, aged 17, 10, and 20 years, respectively. The patients exhibited symptoms of varying severity, necessitating different management strategies. The reactions occurred either immediately or within a few minutes after the onset of cyclosporine infusion and were often worsened by rechallenge. In all cases, cyclosporine was eventually replaced with tacrolimus or sirolimus. A comprehensive literature review was conducted to investigate the basis of severe immunoglobulin E-mediated hypersensitivity reactions to calcineurin inhibitors in patients with thalassemia major undergoing hematopoietic stem cell transplantation. Several immunogenic factors may potentially increase the susceptibility of these patients to hypersensitivity reactions to Cremophor-containing medications. While severe reactions to calcineurin inhibitors remain rare, clinicians should be aware of the potential for serious adverse events in patients with thalassemia.Keywords
This publication has 21 references indexed in Scilit:
- Characterization of pediatric transfusion‐dependent thalassemia patients in a large academic centerJournal of Clinical Laboratory Analysis, 2023
- Tacrolimus in adult hematopoietic stem cell transplantationExpert Opinion on Drug Metabolism & Toxicology, 2019
- Hypersensitivity Reaction to Intravenous but Not Oral TacrolimusTransplantation, 2012
- Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimusBone Marrow Transplantation, 2006
- Asthma and Allergic Rhinitis in Patients with Beta-Thalassemia MinorJournal of Allergy and Clinical Immunology, 2006
- A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K1)Bone Marrow Transplantation, 2001
- Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipientBone Marrow Transplantation, 2001
- Cross-sensitivity reaction between tacrolimus and macrolide antibioticsBone Marrow Transplantation, 2000
- Anaphylaxis to Intravenous Cyclosporine and Tolerance to Oral Cyclosporine: Case Report and ReviewAnnals of Allergy, Asthma & Immunology, 1998
- ANAPHYLACTIC REACTION TO INTRAVENOUS CYCLOSPORINThe Lancet, 1984